It’s called the “iLet” (think pancreatic “islets”). The current prototype features a touchscreen interface, chambers for both insulin and glucagon, built-in Dexcom and control algorithm integration, and wireless CGM calibration via a paired blood glucose meter (so you cannot incorrectly enter the meter value). Dr. Edward Damiano hopes to improve the iLet by making it smaller and enhancing the touchscreen over the next nine months; it will ideally be used in a human factors study with a custom-designed infusion set in 2016. The hope is for a pivotal study to take place across the United States from early 2017 to early 2018, and an FDA review to overlap from late 2017 to late 2018. It’s an ambitious timeline requiring many things to go right, though it means the device could be available as soon as late 2018 or early 2019. Check out the video interview from one of the developers, Firas El-Khatib, PhD.